Out-of-Pocket Costs for Infliximab and Its Biosimilar for Rheumatoid Arthritis Under Medicare Part D

Documenti analoghi

• Coverage For High Cost Specialty Drugs for Rheumatoid Arthritis in Medicare Part D
  di: Yazdany, Jinoos, et al.
  Pubblicazione: (2015)
• Assessment of National Coverage and Out-of-Pocket Costs for Sacubitril/Valsartan Under Medicare Part D
  di: DeJong, Colette, et al.
  Pubblicazione: (2019)
• Out-of-Pocket Costs for Novel Guideline-Directed Diabetes Therapies Under Medicare Part D
  di: DeJong, Colette, et al.
  Pubblicazione: (2020)
• Impact of Higher Insulin Prices on Out-of-Pocket Costs in Medicare Part D
  di: Tseng, Chien-Wen, et al.
  Pubblicazione: (2020)
• Medicare Part D plans’ coverage and cost-sharing for acute rescue and preventive inhalers for chronic obstructive pulmonary disease
  di: Tseng, Chien-Wen, et al.
  Pubblicazione: (2017)